Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with ribociclib and standard of care endocrine treatment according to SmPC.

Trial Details

NCT ID
NCT05452213
Phase
PHASE4
Sponsor
Institut fuer Frauengesundheit
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • Ribociclib
Locations (sample)
  • Erlangen, Bavaria, Germany|49.59099,11.00783
  • Mainz, Hesse, Germany
  • Bottrop, North Rhine-Westphalia, Germany|51.52392,6.9285
  • Amberg, Germany|49.44287,11.86267
  • Aschaffenburg, Germany|49.97704,9.15214

Key Eligibility Criteria

  • Indication for treatment with ribociclib in combination with endocrine therapy in the locally advanced or 1st line metastatic therapy setting accor…
  • Written informed consent prior to beginning of trial specific procedures
  • Subject must be female and aged ≥ 18 years on the day of signing informed consent
  • Locally advanced or metastatic breast cancer not amenable to curative treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →